1100 13th Street, NW, Suite 750Washington, DC 20005202.887.6400Toll-free: 800.544.0155
All Contents © 2016The Kiplinger Washington Editors
See All Authors »
David Milstead is a Denver-based freelancer who writes "Vox," a markets and investing column for The Globe and Mail, the national newspaper of Canada. Previously, he was finance editor of Denver's Rocky Mountain News until it closed in 2009.
If you want to invest in stocks, we have two words of advice: Go global.
With the U.S. accounting for just 22% of the world’s economic activity, it’s hard to justify owning only domestic stocks. ...
See More From: Stocks & Bonds
When we searched for great stocks around the world, we had a few simple requirements. First, the stocks had to trade on a U.S. exchange, whether the companies were based in the U.S. or overseas. Next, ...
Gilead Sciences, the largest biotech company, has a P/E ratio of only 11.
See More From: Stock Watch
As companies look to unlock value by breaking up, investors have a variety of opportunities.
Looking for a foothold in the Chinese market with dividends to boot? Consider this threesome.
Of the four major players, we like Priceline and Expedia best.
Even though the stock’s offering price is still unknown, a lot of the hype surrounding China’s leading e-commerce firm is justified.
Shares of these three eateries aren't cheap, but they have superior growth prospects.
The company's first earnings report since going public could shed light on whether the richly priced shares are worth it.
Just because shares trade for four figures doesn't mean they're pricey. Take Google and Priceline, for example.
These stocks have suffered since going public, but their prospects are starting to look up.
Investors are treating the maker of battery-operated cars like a dot-com. Ford and GM are better deals.
The American jobs machine is showing signs of life. These companies are bound to benefit.
These companies build the tools that can help keep us safer.